Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/69320

Type
Article
Copyright
Restricted access
Embargo date
2030-12-31
Collections
Share

Statistics
Metadata
Show full item record

FEATURES OF HIV INFECTION IN LONG-ACTING CABOTEGRAVIR PREEXPOSURE PROPHYLAXIS
Landovitz, Raphael J. et al. | Date Issued: 2024
Author
Landovitz, Raphael J.
Delany-Moretlwe, Sinead
Fogel, Jessica M.
Marzinke, Mark A.
Piwowar-Manning, Estelle
Richardson, Paul
Halvas, Elias K.
Mellors, John W.
Persaud, Deborah
Kofron, Ryan
McCauley, Marybeth
Rose, B. S. Scott
Rinehart, Alex R.
Rooney, James F.
Adeyeye, Adeola
Cohen, Myron S.
Donnell, Deborah
Hosseinipour, Mina C.
Grinsztejn, Beatriz
Eshleman, Susan H.
Affilliation
University of California. Los Angeles, Los Angeles, CA, USA.
University of the Witwatersrand. Johannesburg, South Africa.
Johns Hopkins University. Baltimore, MD, USA.
Johns Hopkins University. Baltimore, MD, USA.
Johns Hopkins University. Baltimore, MD, USA.
Johns Hopkins University. Baltimore, MD, USA.
University of Pittsburgh. Pittsburgh, PA, USA.
University of Pittsburgh. Pittsburgh, PA, USA.
Johns Hopkins University. Baltimore, MD, USA.
University of California. Los Angeles, Los Angeles, CA, USA.
FHI 360. Durham, NC, USA.
FHI 360. Durham, NC, USA.
ViiV Healthcare Research. Triangle Park, NC, USA.
Gilead Sciences. Foster City, CA, USA.
National Institutes of Health. Rockville, MD, USA.
University of North Carolina at Chapel Hill. Chapel Hill, NC, USA.
Fred Hutchinson Cancer Center. Seattle, WA, USA.
University of North Carolina at Chapel Hill. Chapel Hill, NC, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST e AIDS. Rio de Janeiro, RJ, Brasil.
Johns Hopkins University School of Medicine. Baltimore, MD, USA.
Abstract
Preexposure prophylaxis is emerging as an important tool to prevent HIV-1 infection. This report describes an altered presentation of acute HIV infection that may occur with use of long-acting cabotegravir PrEP.
Keywords
HIV
Cabotegravir
Pre-exposure prophylaxis (PrEP)
 
Publisher
Massachusetts Medical Society
Citation
LANDOVITZ, Raphael J. et al. Features of HIV Infection in Long-Acting Cabotegravir PreExposure Prophylaxis. The New England Journal of Medicine, v. 391, n. 13, p. 1-4, Oct. 2024.
Previous version
https://www.arca.fiocruz.br/handle/icict/68324
DOI
10.1056/NEJMc2402088
ISSN
0028-4793
Notes
Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.
Collaborators: HPTN 083 and 084 Study Teams: Raphael J Landovitz, Sinead Delany-Moretlwe, Jessica M Fogel, Mark A Marzinke, Estelle Piwowar-Manning, Paul Richardson, Elias K Halvas, John W Mellors, Deborah Persaud, Ryan Kofron, Marybeth McCauley, Scott Rose, Alex R Rinehart, James F Rooney, Adeola Adeyeye, Myron S Cohen, Deborah Donnell, Mina C Hosseinipour, Beatriz Grinsztejn, Susan H Eshleman.